Welcome to our dedicated page for Virios Therapeutics SEC filings (Ticker: VIRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching for the latest developments on Virios Therapeutics’ antiviral pipeline often starts with a single question: where in hundreds of SEC pages can I find the numbers and study updates that move the stock? On this page you’ll locate every Virios Therapeutics SEC filing explained simply, from the annual report 10-K that breaks down R&D spend to the 8-K material events explained when new clinical data emerges.
Our AI-powered summaries strip out jargon so understanding Virios Therapeutics SEC documents with AI feels natural. Need fast access to a Virios Therapeutics quarterly earnings report 10-Q filing? We highlight cash runway, trial costs, and variance from previous quarters. Tracking leadership confidence? Real-time alerts surface Virios Therapeutics Form 4 insider transactions the moment they hit EDGAR, letting you spot Virios Therapeutics executive stock transactions Form 4 before the market digests them.
Use cases professionals rely on include:
- Compare R&D burn across quarters with one-click Virios Therapeutics earnings report filing analysis.
- Review Virios Therapeutics proxy statement executive compensation to gauge alignment with shareholders.
- Dive into shelf registrations to understand dilution risk without wading through legal text.
Whether you’re assessing phase-two trial momentum or monitoring a Virios Therapeutics insider trading Form 4 transactions cluster, Stock Titan delivers comprehensive coverage: every 10-K, 10-Q, 8-K, S-1, and more, updated in real time. Investors, analysts, and healthcare professionals save hours while our expert analysis links each disclosure to the science that underpins Virios Therapeutics’ potential.
Dogwood Therapeutics is a pre-revenue biopharmaceutical company focused on its Na v 1.7 program Halneuron and antiviral combinations; after the October 2024 Combination the company reports total assets of $96.7M including capitalized IPR&D of $69.3M and goodwill of $12.46M. Cash totaled $13.40M at June 30, 2025 and net cash used in operating activities was $8.71M for the six months.
Dogwood recorded net losses of $3.81M for the quarter and $14.73M year-to-date, producing an accumulated deficit of $88.55M and basic/diluted net loss per common share of $(1.99) (quarter) and $(9.51) (six months). The company completed a registered direct offering (net proceeds ~$4.25M) and converted related-party debt into Series A-1 preferred (debt extinguishment of ~$19.9M with a recognized loss of $6.13M). Management discloses substantial doubt about the company’s ability to continue without additional financing beyond the first quarter of 2026.
Dogwood Therapeutics, Inc. furnished a press release reporting its results of operations for the quarter ended June 30, 2025, which is included as Exhibit 99.1 and is incorporated by reference into Item 2.02 of this Current Report.
The Form notes the information is being furnished, not filed, so it is not subject to Section 18 liability and is not incorporated by reference into other filings. The registrant identifies as an emerging growth company and did not check the box indicating an election to forgo the extended transition period. The company’s common stock trades on the Nasdaq Capital Market under ticker DWTX. The report is signed by Angela Walsh, Chief Financial Officer, Corporate Secretary and Treasurer.
FAQ
What is the current stock price of Virios Therapeutics (VIRI)?
What is the market cap of Virios Therapeutics (VIRI)?
